Optimized lentiviral transfer vectors and uses thereof

Abstract

The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.

What is claimed is: 
     
         1 . A lentiviral transfer vector comprising a heterologous nucleic acid sequence and being characterized by at least three of the following features:
 (a) comprising a cytomegalovirus (CMV) promoter,   (b) comprising a polynucleotide encoding at least a portion of a gag protein that comprises a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA relative to wild-type INS1,   (c) not comprising a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag, and   (d) not comprising an SV40 origin of replication and/or an f1 origin of replication.   
     
     
         2 . The lentiviral transfer vector of  claim 1 , characterized by features (b)-(d). 
     
     
         3 . The lentiviral transfer vector of  claim 1 , characterized by features (a)-(c); (a), (b), and (d); or (a), (c), and (d). 
     
     
         4 . The lentiviral transfer vector of  claim 1 , comprising (a) a polynucleotide encoding a 150-250 (e.g., 168) nucleotide portion of a gag protein that (i) comprises a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA relative to wild-type INS1, (H) contains two nucleotide insertion that results in frame shift and premature termination, and/or (iii) does not comprise INS2, INS3, and INS4 inhibitory sequences, or (b) one or more elements selected from the group consisting of (i) a packaging signal (psi), (ii) a partial gag sequence adjacent to or partially overlapping with psi, (iii) a rev-response element, (iv) a partial env sequence, and (v) a cPPT sequence from pol, the sequence of which optionally originates from HIV-1 isolate NL4-3 or SF3 and/or optionally comprises about 150-250 (e.g., 178-181) nucleotides and comprises splice acceptor SA1 sequence. 
     
     
         5 - 6 . (canceled) 
     
     
         7 . The lentiviral transfer vector of  claim 1 , further comprising one or more restriction sites positioned between elements of said vector. 
     
     
         8 . The lentiviral transfer vector of  claim 1 , further comprising a post-transcriptional regulatory element (PRE). 
     
     
         9 . The lentiviral transfer vector of  claim 8 , wherein said PRE is a woodchuck hepatitis virus PRE (W PRE), which optionally comprises a nucleic acid sequence having at least 95% identity to SEQ ID NO: 78; or is a hepatitis B virus isolate bba6 PRE (HPRE), which optionally comprises a nucleic acid sequence having at least 95% identity to SEQ ID NO: 79, and optionally comprises an inactivating mutation in an X protein coding sequence. 
     
     
         10 - 12 . (canceled) 
     
     
         13 . The lentiviral transfer vector of  claim 1 , further comprising an EF1a promoter, optionally wherein said EF1a promoter comprises a nucleic acid sequence having at least 95% identity to SEQ ID NO: 71, and optionally is full length and comprises intact splice donor and splice acceptor sequences (SEQ ID NOs:72 and 73, respectively) (SEQ ID NO:95). 
     
     
         14 . The lentiviral transfer vector of  claim 1 , wherein the lentiviral components of said lentiviral transfer vector originate from HIV-1. 
     
     
         15 . The lentiviral transfer vector of  claim 1 , wherein said heterologous nucleic acid sequence is downstream of a Kozak sequence. 
     
     
         16 . (canceled) 
     
     
         17 . The lentiviral transfer vector of  claim 1 , wherein said lentiviral transfer vector comprises:
 (i) a CMV promoter comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 52,   (ii) an LTR R region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 53,   (iii) an LTR U5 region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 54,   (iv) a primer binding site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 55,   (v) a packaging signal comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 56,   (vi) a major splice donor site comprising a nucleic acid sequence having at east 95% identity to SEQ ID NO: 57, which is within said packaging signal,   (vii) a partial gag sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:58,   (viii) a partial env sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:60,   (ix) a Rev-response element comprising a nucleic add sequence having at least 95% identity to SEQ ID NO: 62,   (x) a partial env sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:64,   (xi) a splice acceptor site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 65, which is within said partial env sequence of part (x),   (xii) a central polypurine tract comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 67, 92, or 93,   (xiii) a splice acceptor site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 68 or 94, which is within said central polypurine tract,   (xiv) an EF1 alpha promoter having at least 95% sequence identity to SEQ ID NO:71 or 95,   (xv) a constitutive splice donor (CD) site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 72, which is within said EF1 alpha promoter,   (xvi) a constitutive splice acceptor (CA) site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 73, which is within said EF1 alpha promoter,   (xvii) a polynucleotide encoding an EGFP comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 76 and/or a transgene sequence,   (xviii) a PRE sequence comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 78 or 79,   (xix) a partial nef sequence comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:83,   (xx) a dU3 sequence comprising a nucleic acid sequencing having at least 95% sequence identity to SEQ ID NO:84,   (xxi) an LTR R region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 85, and   (xxii) an LTR U5 region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 86.   
     
     
         18 . The lentiviral transfer vector of  claim 1 , wherein said heterologous nucleic acid sequence encodes a protein chimeric antigen receptor (CAR) comprising, in a N-terminal to C-terminal direction, an antigen binding domain, a transmembrane domain, and one or more signaling domains, and optionally the antigen binding domain is an scFV. 
     
     
         19 - 22 . (canceled) 
     
     
         23 . The lentiviral transfer vector of  claim 18 , wherein one of said one or more primary signaling domains comprises a primary signaling domain comprising a CD3-zeta stimulatory domain. 
     
     
         24 . The lentiviral transfer vector of  claim 18 , wherein one or more of said one or more signaling domains comprises a costimulatory domain comprising an intracellular domain of a costimulatory protein selected from the group consisting of CD27, CD28, 4-1 BB (CD137), OX40, GITR, CD30, CD40, ICOS, BAFFR, HVEM, ICAM-1, lymphocyte function-associated antigen-1 (LFA-1), CD2, CDS, CD7, CD287, LIGHT, NKG2C, NKG2D, SLAMF7, NKp80, NKp30, NKp44, NKp46, CD160, B7-H3, and a ligand that specifically binds with CD83. 
     
     
         25 - 27 . (canceled) 
     
     
         28 . The lentiviral transfer vector of  claim 18 , wherein said antigen binding domain binds to an antigen selected from the group consisting of CD19; CD123; CD22; CD30; CD171; CS-1; C-type lectin-like molecule-1, CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3; TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAca-Ser/Thr)); prostate-specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-Like Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); Interleukin-13 receptor subunit alpha-2; mesothelin; Interleukin 11 receptor alpha (IL-11 Ra); prostate stem cell antigen (PSCA); Protease Serine 21; vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet-derived growth factor receptor beta (PDGFR-beta); Stage-specific embryonic antigen-4 (SSEA-4); CD20; Folate receptor alpha; Receptor tyrosine-protein kinase ERBB2 (Her2/neu); Mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); Prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); Ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100 (gp100); oncogene fusion protein consisting of breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl) (bcr-abl); tyrosinase; ephrin type-A receptor 2 (EphA2); Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3; transglutaminase 5 (TGS5); high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-CD2 ganglioside (OAcGD2); Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51 E2 (OR51 E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen 2 (LACE-1a); Melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 1 7 (SPA17); X Antigen Family, Member 1 A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; surviving; telomerase; prostate carcinoma tumor antigen-1, melanoma antigen recognized by T cells 1; Rat sarcoma (Ras) mutant; human Telomerase reverse transcriptase (INERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Tyrosinase-related protein 2 (TRP-2); Cytochrome P450 1 B1 (CYP1 B1); CCCTC-Binding Factor (Zinc Anger Protein)-Like, Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Receptor for Advanced Glycation Endproducts (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papilloma virus E6 (HPV E6); human papilloma virus E7 (HPV E7); intestinal carboxyl esterase; heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1). 
     
     
         29 . (canceled) 
     
     
         30 . The lentiviral transfer vector of  claim 18 , wherein said CAR comprises an anti-CD19 antibody or a fragment thereof, a 4-1 BB (CD137) transmembrane domain, and a CD3-zeta signaling domain. 
     
     
         31 . A lentiviral transfer vector comprising, from 5′ to 3′, one or more of the following elements in operable association:
 a promoter, 
 a packaging signal (psi) comprising a major splice donor site (SD), 
 a partial gag sequence, 
 a partial env sequence, 
 a Rev-response element (RRE), 
 a partial env sequence comprising splice acceptor site (SA7), 
 a central polypurine tract (cPPT) comprising a splice acceptor site (SA1), 
 an EF1 a promoter, which comprises a constitutive splice donor site (CD) and a constitutive splice acceptor site (CD), 
 optionally a gene encoding EGFP and/or a heterologous nucleic acid sequence, and 
 a post-transcriptional regulatory element. 
 
     
     
         32 - 35 . (canceled) 
     
     
         36 . A host cell or composition comprising the lentiviral transfer vector of  claim 1  and optionally one or more lentiviral packaging vectors. 
     
     
         37 - 39 . (canceled) 
     
     
         40 . A method of producing a lentivirus capable of expressing a heterologous nucleic acid sequence, said method comprising:
 (a) introducing into a cell:
 (i) the lentiviral transfer vector of  claim 1 , and 
 (ii) one or more lentiviral packaging vectors; and 
   (b) expressing viral proteins encoded by said lentiviral transfer vector and/or said packaging vector in said cell, thereby producing a lentivirus comprising the heterologous nucleic acid sequence of said lentiviral transfer vector.   
     
     
         41 . (canceled) 
     
     
         42 . A method of expressing a transgene in a cell, the method comprising producing a lentivirus by the method of  claim 40  in the cell.